

Global Malignant Melanoma Drug Market Professional Survey Report 2016

https://marketpublishers.com/r/GE7737E8773EN.html Date: June 2016 Pages: 112 Price: US\$ 3,500.00 (Single User License) ID: GE7737E8773EN **Abstracts** This report mainly covers the following Product types including **Immunotherapy** Targeted therapy Others The segment applications including Hospital use Clinic use Segment regions including (the separated region report can also be offered) North America Europe

Japan



China Southeast Asia India The players list (Partly, Players you are interested in can also be added) **AB Science AVAX Technologies** Biogen Idec BioVex Bristol-Myers Squibb **Enzon Pharmaceuticals** Eisai Co **Exelixis** GlaxoSmithKline Lorus Therapeutics (Aptose Bioscience) Medarex Merck Navidea Biopharmaceuticals **Novartis** Ono Pharmaceutical



Onyx Pharmaceuticals
Pfizer
Pharmalucence (Sun Pharmaceutical Industries Limited)
Plexxikon
QIAGEN
Roche

With no less than 10 top producers.

Data including (both global and regions): Market Size (both volume - Unit and value - million USD), Market Share, Production data, Consumption data, Trade data, Price - USD/Unit, Cost, Gross margin etc.

More detailed information, please refer to the attachment file and table of contents. If you have other requirements, please contact us, we can also offer!



Contents

1 INDUSTRY OVERVIEW OF MALIGNANT MELANOMA DRUG

- 1.1 Definition and Specifications of Malignant Melanoma Drug
 - 1.1.1 Definition of Malignant Melanoma Drug
 - 1.1.2 Specifications of Malignant Melanoma Drug
- 1.2 Classification of Malignant Melanoma Drug
 - 1.2.1 Immunotherapy
 - 1.2.2 Targeted therapy
 - 1.2.3 Others
- 1.3 Applications of Malignant Melanoma Drug
 - 1.3.1 Hospital use
 - 1.3.2 Clinic use
- 1.4 Industry Chain Structure of Malignant Melanoma Drug
- 1.5 Industry Overview and Major Regions Status of Malignant Melanoma Drug
 - 1.5.1 Industry Overview of Malignant Melanoma Drug
- 1.5.2 Global Major Regions Status of Malignant Melanoma Drug
- 1.6 Industry Policy Analysis of Malignant Melanoma Drug
- 1.7 Industry News Analysis of Malignant Melanoma Drug

2 MANUFACTURING COST STRUCTURE ANALYSIS OF MALIGNANT MELANOMA DRUG

- 2.1 Raw Material Suppliers and Price Analysis of Malignant Melanoma Drug
- 2.2 Equipment Suppliers and Price Analysis of Malignant Melanoma Drug
- 2.3 Labor Cost Analysis of Malignant Melanoma Drug
- 2.4 Other Costs Analysis of Malignant Melanoma Drug
- 2.5 Manufacturing Cost Structure Analysis of Malignant Melanoma Drug
- 2.6 Manufacturing Process Analysis of Malignant Melanoma Drug

3 TECHNICAL DATA AND MANUFACTURING PLANTS ANALYSIS OF MALIGNANT MELANOMA DRUG

- 3.1 Capacity and Commercial Production Date of Global Malignant Melanoma Drug Major Manufacturers in 2015
- 3.2 Manufacturing Plants Distribution of Global Malignant Melanoma Drug Major Manufacturers in 2015
- 3.3 R&D Status and Technology Source of Global Malignant Melanoma Drug Major



Manufacturers in 2015

3.4 Raw Materials Sources Analysis of Global Malignant Melanoma Drug Major Manufacturers in 2015

4 GLOBAL MALIGNANT MELANOMA DRUG OVERALL MARKET OVERVIEW

- 4.1 2011-2016E Overall Market Analysis
- 4.2.1 2011-2015 Global Malignant Melanoma Drug Capacity and Growth Rate Analysis
- 4.2.2 2015 Malignant Melanoma Drug Capacity Analysis (Company Segment)
- 4.3 Sales Analysis
 - 4.3.1 2011-2015 Global Malignant Melanoma Drug Sales and Growth Rate Analysis
- 4.3.2 2015 Malignant Melanoma Drug Sales Analysis (Company Segment)
- 4.4 Sales Price Analysis
 - 4.4.1 2011-2015 Global Malignant Melanoma Drug Sales Price
- 4.4.2 2015 Malignant Melanoma Drug Sales Price Analysis (Company Segment)
- 4.5 Gross Margin Analysis
 - 4.5.1 2011-2015 Global Malignant Melanoma Drug Gross Margin
 - 4.5.2 2015 Malignant Melanoma Drug Gross Margin Analysis (Company Segment)

5 MALIGNANT MELANOMA DRUG REGIONAL MARKET ANALYSIS

- 5.1 North America Malignant Melanoma Drug Market Analysis
- 5.1.1 North America Malignant Melanoma Drug Market Overview
- 5.1.2 North America 2011-2016E Malignant Melanoma Drug Local Supply, Import, Export, Local Consumption Analysis
 - 5.1.3 North America 2011-2016E Malignant Melanoma Drug Sales Price Analysis
- 5.1.4 North America 2015 Malignant Melanoma Drug Market Share Analysis
- 5.2 Europe Malignant Melanoma Drug Market Analysis
 - 5.2.1 Europe Malignant Melanoma Drug Market Overview
- 5.2.2 Europe 2011-2016E Malignant Melanoma Drug Local Supply, Import, Export, Local Consumption Analysis
 - 5.2.3 Europe 2011-2016E Malignant Melanoma Drug Sales Price Analysis
 - 5.2.4 Europe 2015 Malignant Melanoma Drug Market Share Analysis
- 5.3 Japan Malignant Melanoma Drug Market Analysis
 - 5.3.1 Japan Malignant Melanoma Drug Market Overview
- 5.3.2 Japan 2011-2016E Malignant Melanoma Drug Local Supply, Import, Export, Local Consumption Analysis
 - 5.3.3 Japan 2011-2016E Malignant Melanoma Drug Sales Price Analysis



- 5.3.4 Japan 2015 Malignant Melanoma Drug Market Share Analysis
- 5.4 China Malignant Melanoma Drug Market Analysis
- 5.4.1 China Malignant Melanoma Drug Market Overview
- 5.4.2 China 2011-2016E Malignant Melanoma Drug Local Supply, Import, Export, Local Consumption Analysis
- 5.4.3 China 2011-2016E Malignant Melanoma Drug Sales Price Analysis
- 5.4.4 China 2015 Malignant Melanoma Drug Market Share Analysis
- 5.5 Southeast Asia Malignant Melanoma Drug Market Analysis
- 5.5.1 Southeast Asia Malignant Melanoma Drug Market Overview
- 5.5.2 Southeast Asia 2011-2016E Malignant Melanoma Drug Local Supply, Import, Export, Local Consumption Analysis
- 5.5.3 Southeast Asia 2011-2016E Malignant Melanoma Drug Sales Price Analysis
- 5.5.4 Southeast Asia 2015 Malignant Melanoma Drug Market Share Analysis
- 5.6 India Malignant Melanoma Drug Market Analysis
- 5.6.1 India Malignant Melanoma Drug Market Overview
- 5.6.2 India 2011-2016E Malignant Melanoma Drug Local Supply, Import, Export, Local Consumption Analysis
 - 5.6.3 India 2011-2016E Malignant Melanoma Drug Sales Price Analysis
 - 5.6.4 India 2015 Malignant Melanoma Drug Market Share Analysis

6 GLOBAL 2011-2016E MALIGNANT MELANOMA DRUG SEGMENT MARKET ANALYSIS (BY TYPE)

- 6.1 Global 2011-2016E Malignant Melanoma Drug Sales by Type
- 6.2 Different Types Malignant Melanoma Drug Product Interview Price Analysis
- 6.3 Different Types Malignant Melanoma Drug Product Driving Factors Analysis
- 6.3.1 Immunotherapy Malignant Melanoma Drug Growth Driving Factor Analysis
- 6.3.2 Targeted therapy Malignant Melanoma Drug Growth Driving Factor Analysis
- 6.3.3 Others Malignant Melanoma Drug Growth Driving Factor Analysis

7 GLOBAL 2011-2016E MALIGNANT MELANOMA DRUG SEGMENT MARKET ANALYSIS (BY APPLICATION)

- 7.1 Global 2011-2016E Consumption by Application
- 7.2 Different Application Product Interview Price Analysis
- 7.3 Different Application Product Driving Factors Analysis
- 7.3.1 Hospital use Malignant Melanoma Drug Growth Driving Factor Analysis
- 7.3.2 Clinic use Malignant Melanoma Drug Growth Driving Factor Analysis



8 MAJOR MANUFACTURERS ANALYSIS OF MALIGNANT MELANOMA DRUG

- 8.2 AB Science
 - 8.2.1 Company Profile
 - 8.2.2 Product Picture and Specifications
- 8.2.3 AB Science 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.2.4 AB Science 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.3 AVAX Technologies
 - 8.3.1 Company Profile
 - 8.3.2 Product Picture and Specifications
- 8.3.3 AVAX Technologies 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.3.4 AVAX Technologies 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.4 Biogen Idec
 - 8.4.1 Company Profile
 - 8.4.2 Product Picture and Specifications
- 8.4.3 Biogen Idec 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.4.4 Biogen Idec 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.5 BioVex
 - 8.5.1 Company Profile
 - 8.5.2 Product Picture and Specifications
- 8.5.3 BioVex 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.5.4 BioVex 2015 Malignant Melanoma Drug Business Region Distribution Analysis 8.6 Bristol-Myers Squibb
 - 8.6.1 Company Profile
 - 8.6.2 Product Picture and Specifications
- 8.6.3 Bristol-Myers Squibb 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.6.4 Bristol-Myers Squibb 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.7 Enzon Pharmaceuticals
 - 8.7.1 Company Profile
 - 8.7.2 Product Picture and Specifications



- 8.7.3 Enzon Pharmaceuticals 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.7.4 Enzon Pharmaceuticals 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.8 Eisai Co
 - 8.8.1 Company Profile
 - 8.8.2 Product Picture and Specifications
- 8.8.3 Eisai Co 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue,
- Gross Margin Analysis
- 8.8.4 Eisai Co 2015 Malignant Melanoma Drug Business Region Distribution Analysis 8.9 Exelixis
 - 8.9.1 Company Profile
 - 8.9.2 Product Picture and Specifications
- 8.9.3 Exelixis 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.9.4 Exelixis 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.10 GlaxoSmithKline
 - 8.10.1 Company Profile
 - 8.10.2 Product Picture and Specifications
- 8.10.3 GlaxoSmithKline 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.10.4 GlaxoSmithKline 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.11 Lorus Therapeutics (Aptose Bioscience)
 - 8.11.1 Company Profile
 - 8.11.2 Product Picture and Specifications
- 8.11.3 Lorus Therapeutics (Aptose Bioscience) 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.11.4 Lorus Therapeutics (Aptose Bioscience) 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.12 Medarex
 - 8.12.1 Company Profile
 - 8.12.2 Product Picture and Specifications
- 8.12.3 Medarex 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.12.4 Medarex 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.13 Merck
 - 8.13.1 Company Profile



- 8.13.2 Product Picture and Specifications
- 8.13.3 Merck 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.13.4 Merck 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.14 Navidea Biopharmaceuticals
 - 8.14.1 Company Profile
 - 8.14.2 Product Picture and Specifications
- 8.14.3 Navidea Biopharmaceuticals 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.14.4 Navidea Biopharmaceuticals 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.15 Novartis
 - 8.15.1 Company Profile
 - 8.15.2 Product Picture and Specifications
- 8.15.3 Novartis 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.15.4 Novartis 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.16 Ono Pharmaceutical
 - 8.16.1 Company Profile
 - 8.16.2 Product Picture and Specifications
- 8.16.3 Ono Pharmaceutical 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.16.4 Ono Pharmaceutical 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.17 Onyx Pharmaceuticals
 - 8.17.1 Company Profile
 - 8.17.2 Product Picture and Specifications
- 8.17.3 Onyx Pharmaceuticals 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.17.4 Onyx Pharmaceuticals 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.18 Pfizer
 - 8.18.1 Company Profile
 - 8.18.2 Product Picture and Specifications
- 8.18.3 Pfizer 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
 - 8.18.4 Pfizer 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.19 Pharmalucence (Sun Pharmaceutical Industries Limited)
 - 8.19.1 Company Profile



- 8.19.2 Product Picture and Specifications
- 8.19.3 Pharmalucence (Sun Pharmaceutical Industries Limited) 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.19.4 Pharmalucence (Sun Pharmaceutical Industries Limited) 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.20 Plexxikon
 - 8.20.1 Company Profile
 - 8.20.2 Product Picture and Specifications
- 8.20.3 Plexxikon 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.20.4 Plexxikon 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.21 QIAGEN
 - 8.21.1 Company Profile
 - 8.21.2 Product Picture and Specifications
- 8.21.3 QIAGEN 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.21.4 QIAGEN 2015 Malignant Melanoma Drug Business Region Distribution Analysis
- 8.22 Roche
 - 8.22.1 Company Profile
 - 8.22.2 Product Picture and Specifications
- 8.22.3 Roche 2015 Malignant Melanoma Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
- 8.22.4 Roche 2015 Malignant Melanoma Drug Business Region Distribution Analysis

9 DEVELOPMENT TREND OF ANALYSIS OF MARKET

- 9.1 Global Market Trend Analysis
 - 9.1.1 Global 2016-2021 Market Size (Volume and Value) Forecast
 - 9.1.2 Global 2016-2021 Sales Price Forecast
 - 9.1.3 Global 2016-2021 Gross Margin Forecast
- 9.2 Regional Market Trend
 - 9.2.1 North America 2016-2021 Malignant Melanoma Drug Consumption Forecast
 - 9.2.2 Europe 2016-2021 Malignant Melanoma Drug Consumption Forecast
 - 9.2.3 Japan 2016-2021 Malignant Melanoma Drug Consumption Forecast
 - 9.2.4 China 2016-2021 Malignant Melanoma Drug Consumption Forecast
 - 9.2.5 Southeast Asia 2016-2021 Malignant Melanoma Drug Consumption Forecast
 - 9.2.6 India 2016-2021 Malignant Melanoma Drug Consumption Forecast



- 9.3 Market Trend (Product type)
- 9.4 Market Trend (Application)

10 MALIGNANT MELANOMA DRUG MARKETING MODEL ANALYSIS

- 10.1 Malignant Melanoma Drug Regional Marketing Model Analysis
- 10.2 Malignant Melanoma Drug International Trade Model Analysis
- 10.3 Traders or Distributors with Contact Information of Malignant Melanoma Drug by Regions
- 10.4 Malignant Melanoma Drug Supply Chain Analysis

11 CONSUMERS ANALYSIS OF MALIGNANT MELANOMA DRUG

- 11.1 Consumer 1 Analysis
- 11.2 Consumer 2 Analysis
- 11.3 Consumer 3 Analysis
- 11.4 Consumer 4 Analysis

12 NEW PROJECT INVESTMENT FEASIBILITY ANALYSIS OF MALIGNANT MELANOMA DRUG

- 12.1 New Project SWOT Analysis of Malignant Melanoma Drug
- 12.2 New Project Investment Feasibility Analysis of Malignant Melanoma Drug

13 CONCLUSION OF THE GLOBAL MALIGNANT MELANOMA DRUG MARKET PROFESSIONAL SURVEY REPORT 2016



I would like to order

Product name: Global Malignant Melanoma Drug Market Professional Survey Report 2016

Product link: https://marketpublishers.com/r/GE7737E8773EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GE7737E8773EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970